Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05128032 · ClinicalTrials.gov registry record · NA
Pressure-enabled Delivery in Radioembolization (TriNav Study)
A NA study of Hepatocellular Carcinoma and Liver Cancer, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT05128032: Active NA study of Hepatocellular Carcinoma and Liver Cancer, sponsored by Massachusetts General Hospital.
NCT05128032 is a NA study of Hepatocellular Carcinoma and Liver Cancer that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 20 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05128032, a NA study of Hepatocellular Carcinoma and Liver Cancer, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of the study is to determine if the type of catheter used in the mapping procedure prior to radioembolization improves the delivery of radioactivity to tumor(s) in participants with liver cancer. The name of the devices involved in this study are: * Pressure Enabled Drug Delivery (PEDD)/TriNav Infusion System * Standard 2.4F microcatheter, not otherwise specified
Primary Outcome
The primary endpoint of the study is radiotracer distribution, as measured by tumor to normal liver (T:N) ratio. Using SPECT/CT images collected subsequent to radiotracer delivery in mapping procedures, the volumetric tumor to normal liver (T:N) ratio of 99mTc-MAA distribution will be calculated using advanced imaging processing software, such as MIM SurePlan MRT. The T:N ratio of 99mTc-MAA delivered via the standard microcatheter will be compared to the PEDD device for each patient. The T:N rat
Conditions Studied
Interventions
- DEVICE Standard microcatheter
- DEVICE PEDD device
Study Locations (2)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-03-01 |
| Est. Completion | 2026-09-01 |
| Phase | NA |
What the registry record for NCT05128032 still lists
NCT05128032 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (92% lower).
The record links to 3 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Standard microcatheter is the first listed.
NCT05128032 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05128032 about?
NCT05128032 is a clinical study titled "Pressure-enabled Delivery in Radioembolization (TriNav Study)". The purpose of the study is to determine if the type of catheter used in the mapping procedure prior to radioembolization improves the delivery of radioactivity to tumor(s) in participants with liver cancer. The name of the devices involved in this study are: * Pressure Enabled Drug Delivery (PEDD...
What is the current status of trial NCT05128032?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2022-03-01. Estimated completion is 2026-09-01.
What conditions does trial NCT05128032 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Liver Cancer, Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT05128032?
The interventions under investigation include: Standard microcatheter (DEVICE), PEDD device (DEVICE).
Who is sponsoring clinical trial NCT05128032?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05128032 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05128032's enrollment target sits among peer trials
20 123rd of 145 higher than 16 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
RECRUITING · NA
-
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
RECRUITING · NA
-
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
RECRUITING · NA
-
Psychoeducational Intervention for Patients With Hepatocellular Carcinoma
RECRUITING · NA
-
CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI